{"id":"W2948726637","doi":"10.1016/s0140-6736(19)30650-6","title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Health Economics","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research; University of Warwick; Cancer Research UK; University of Cambridge; Department of Health and Social Care","keywords":"Medicine; Trastuzumab; Breast cancer; Clinical endpoint; Internal medicine; Intention-to-treat analysis; Surgery; Randomized controlled trial; Clinical trial; Chemotherapy; Adjuvant; Cancer; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001432073,0.0002316288,0.001284966,0.00007627533,0.00005693538,0.00001756962,0.0005445413,0.0001010336,0.0002365052],"category_scores_gemma":[0.0006811037,0.0001603587,0.0003372109,0.0002170345,0.0002574572,0.00007567597,0.0001061741,0.0003245739,0.00001493041],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002206082,"about_ca_system_score_gemma":0.0008552353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003199551,"about_ca_topic_score_gemma":0.0003438628,"domain_scores_codex":[0.9974186,0.0002354852,0.000579723,0.0003891877,0.0008423572,0.0005346771],"domain_scores_gemma":[0.996875,0.000983323,0.0002712002,0.001271246,0.0003689954,0.0002302564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9797739,0.0005680963,0.002191689,0.0003846337,0.0004513678,0.00001090373,0.001381684,0.00001769949,0.004968294,0.00004573402,0.007070489,0.003135445],"study_design_scores_gemma":[0.9428493,0.004190405,0.0463495,0.0005221438,0.0004230879,0.000001528035,0.0004133355,0.000713841,0.003359855,0.00006540883,0.0009003314,0.0002112252],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9763303,0.0002257549,0.0000423961,0.003456001,0.001089358,0.005517579,0.0102356,0.00003190494,0.003071119],"genre_scores_gemma":[0.9971461,0.0001899343,0.0001322903,0.00006139255,0.001587036,0.000340791,0.00008101645,0.00004715267,0.0004142465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04415781,"threshold_uncertainty_score":0.6539239,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05371163214208088,"score_gpt":0.3732203289132454,"score_spread":0.3195086967711646,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}